Description
Picoplatin is an analog of cisplatin with a 2-methylpyridine ligand that displays anticancer chemotherapeutic activity. Picoplatin is used to treat non-small cell lung cancer (NSCLC) and is in clinical trials as a potential treatment for prostate cancer. Picoplatin intercalates with GpG sequences in DNA and shows efficacy inhibiting tumor growth in vitro, in vivo, and in clinical settings.
References
Matos CS, de Carvalho AL, Lopes RP, et al. New strategies against prostate cancer--Pt(II)-based chemotherapy. Curr Med Chem. 2012;19(27):4678-87. PMID: 22856665.
Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol. 2009 Apr 20;27(12):2046-51. PMID: 19289620.
Kanzawa F, Akiyama Y, Saijo N, et al. In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. Lung Cancer. 2003 Jun;40(3):325-32. PMID: 12781432.
Munk VP, Diakos CI, Ellis LT, et al. Investigations into the interactions between DNA and conformationally constrained pyridylamineplatinum(II) analogues of AMD473. Inorg Chem. 2003 Jun 2;42(11):3582-90. PMID: 12767196.